Search
Asimadoline
go.drugbank.com/drugs/DB05104InvestigationalAsimadoline is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis.
Ephedra sinica root
go.drugbank.com/drugs/DB01363ApprovedNutraceuticalEphedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 d...
Aminolevulinic acid
go.drugbank.com/drugs/DB00855ApprovedInvestigationalA compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
Lenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigational[A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal
Chloropyramine
go.drugbank.com/drugs/DB08800InvestigationalChlorpyramine is a first generation antihistamine used in Eastern European countries to treat bronchial asthma as well as allergice rhinitis, allergic conjunctivitis, and other allergic reactions. It is also indicated for Quincke's edema...
Categories: Antihistamines for Systemic Use, Antihistamines for Topical UseCefacetrile
go.drugbank.com/drugs/DB01414InvestigationalVet approvedA derivative of 7-aminocephalosporanic acid.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseLorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnIt has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety.
Leniolisib
go.drugbank.com/drugs/DB16217ApprovedInvestigational[L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections
DaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational[A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.
Olmesartan
go.drugbank.com/drugs/DB00275ApprovedInvestigational[A175330] It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.[A175345, L12882] … ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling.